Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 239

Sort by

Sort Order Select

Journal Articles

Increased Pentraxin-3 Correlates with the Activity of the Neoplastic Clone in Primary Myelofibrosis

Ivo Veletic, MD, Taghi Manshouri, Kate J Newberry, PhD, Joseph E Bove, IV, Ying Zhang, MDMS, Zeev Estrov, MD, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 5284.

https://doi.org/10.1182/blood.V130.Suppl_1.5284.5284

Published: 2017

Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations

Nitin Jain, MD, Philip A Thompson, MBBS, Jan A. Burger, MD PhD, Gautam Borthakur, MD, Prithviraj Bose, MD, Zeev Estrov, MD, Alessandra Ferrajoli, MD, Koichi Takahashi, MD, Naveen Garg, MD, Xuemei Wang, Varsha Gandhi, PhD, William Plunkett, PhD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Wanda Lopez, RN, Hagop M. Kantarjian, MD, Susan M. O'Brien, MD, Michael J Keating, William G Wierda, MD PhD

Blood (2017) 130 (Supplement 1): 495.

https://doi.org/10.1182/blood.V130.Suppl_1.495.495

Published: 2017

Journal Articles

Blinatumomab in B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease: Initial Results of a Phase II Trial

Abhishek Maiti, MBBS, Hagop M. Kantarjian, MD, Nicholas J Short, MD, Maria Khouri, Koichi Takahashi, MD, Maro Ohanian, DO, Gautam Borthakur, MD, Marina Konopleva, MD PhD, Naval Daver, MD, Zeev Estrov, MD, Yesid Alvarado, MD, Philip A Thompson, MBBS, Nitin Jain, MD, Farhad Ravandi, MBBS, Guillermo Garcia-Manero, MD, Carissa N Cholick, Rita Khouri, Susan M. O'Brien, MD, Elias J. Jabbour, MD

Blood (2017) 130 (Supplement 1): 5038.

https://doi.org/10.1182/blood.V130.Suppl_1.5038.5038

Published: 2017

Journal Articles

Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 815.

https://doi.org/10.1182/blood.V130.Suppl_1.815.815

Published: 2017

Journal Articles

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

Mahesh Swaminathan, MD, Hagop M. Kantarjian, MD, Naval Daver, MD, Gautam Borthakur, MD, Maro Ohanian, DO, Tapan Kadia, MD, Courtney D. DiNardo, MDMSc, Nitin Jain, MD, Zeev Estrov, MD, Alessandra Ferrajoli, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, William G Wierda, MD PhD, Farhad Ravandi, MBBS, Maria Rhona Pinsoy, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 723.

https://doi.org/10.1182/blood.V130.Suppl_1.723.723

Published: 2017

Journal Articles

Absolute Percent Deviation of IGHV Mutation As a Continuum Is Prognostically Relevant in Patients with CLL

Preetesh Jain, MBBS,MDDM,PhD, Jan A. Burger, MD PhD, Graciela Nogueras González, Rashmi Kanagal-Shamanna, MD, Uri Rozovski, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, William G Wierda, MD PhD, Philip A Thompson, MBBS, Nawid Sarwari, MD, Rajyalakshmi Luthra, PhD, Andrew Quesada, Nitin Jain, MD, Alessandra Ferrajoli, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Susan M. O'Brien, MD, Michael J. Keating, MD, Zeev Estrov, MD

Blood (2017) 130 (Supplement 1): 3006.

https://doi.org/10.1182/blood.V130.Suppl_1.3006.3006

Published: 2017

Journal Articles

Omacetaxine Mepesuccinate for Patients with Higher-Risk MDS and CMML after Failure of Hypomethylating Agents: A Phase II Trial

Nicholas J Short, MD, Guillermo Garcia-Manero, MD, Kiran Naqvi, MDMPH, Steven Kornblau, MD, Koichi Takahashi, MD, Guillermo Montalban-Bravo, MD, Rita Khouri, Michael Andreeff, MD PhD, Marina Konopleva, MD PhD, Courtney D. DiNardo, MDMSc, Yesid Alvarado, MD, Marie Ghosn, Zeev Estrov, MD, Prithviraj Bose, MD, Rubiul Islam, Xiao Dong, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD

Blood (2017) 130 (Supplement 1): 2967.

https://doi.org/10.1182/blood.V130.Suppl_1.2967.2967

Published: 2017

Journal Articles

Characteristics and Survival of Patients with Chronic Phase Myelofibrosis and Elevated Blasts (5-9%), and the Effect of Therapy with JAK2 Inhibitor Ruxolitinib

Lucia Masarova, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Jorge E. Cortes, MD, Zeev Estrov, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 201.

https://doi.org/10.1182/blood.V130.Suppl_1.201.201

Published: 2017

Journal Articles

Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial

Blood (2017) 130 (Supplement 1): 429.

https://doi.org/10.1182/blood.V130.Suppl_1.429.429

Published: 2017

Journal Articles

Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center

Lucia Masarova, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Jorge E. Cortes, MD, Zeev Estrov, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 4205.

https://doi.org/10.1182/blood.V130.Suppl_1.4205.4205

Published: 2017

Journal Articles

Overexpression of CD36, Driven By STAT3, Mediates Free Fatty Acid Uptake in CLL Cells

Uri Rozovski, MD, David M. Harris, Ping Li, PhD, Zhiming Liu, Preetesh Jain, MBBS,MDDM,PhD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Prithviraj Bose, MD, Philip A Thompson, MBBS, Nitin Jain, MD, William G Wierda, MD PhD, Michael J. Keating, MD, Zeev Estrov, MD

Blood (2017) 130 (Supplement 1): 4301.

https://doi.org/10.1182/blood.V130.Suppl_1.4301.4301

Published: 2017

Journal Articles

Standardized Targeted Sequencing of 29 Genes with Recurrent Mutations in Chronic Lymphocytic Leukemia (CLL) Helps to Better Define Clinical Correlates and Genomic Hotspots

Blood (2017) 130 (Supplement 1): 4304.

https://doi.org/10.1182/blood.V130.Suppl_1.4304.4304

Published: 2017

Journal Articles

Pattern of Mutational Changes in Patients with Chronic Phase CML Who Are Treated with Frontline TKI and Transform to Blast Phase CML

Preetesh Jain, MBBS,MDDM,PhD, Rashmi Kanagal-Shamanna, MD, Hagop M. Kantarjian, MD, F. Anthony San Lucas, Ahmad Ghorab, MDMSc, Elias J. Jabbour, MD, Issa Ghayas, Koji Sasaki, MD, Tapan Kadia, MD, Zeev Estrov, MD, Farhad Ravandi, MBBS, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 4172.

https://doi.org/10.1182/blood.V130.Suppl_1.4172.4172

Published: 2017

Journal Articles

The Clinical BET Inhibitor, GS-5829, Is Active Against Chronic Lymphocytic Leukemia As Single Agent and in Combination with B-Cell Receptor Signaling Inhibitors

Ekaterina Kim, PhD, Elisa Ten Hacken, PhD, Astrid Clarke, PhD, Michael J. Keating, MD, William G Wierda, MD PhD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Philip A Thompson, MBBS, Zeev Estrov, MD, Jan A. Burger, MD PhD

Blood (2017) 130 (Supplement 1): 3844.

https://doi.org/10.1182/blood.V130.Suppl_1.3844.3844

Published: 2017

Journal Articles

Non-Driver Mutations and Gene Sequence Variants Identified By Targeted Deep Sequencing in Polycythemia Vera and Essential Thrombocythemia

Prajwal Boddu, MD, Alay Mansurov, Lucia Masarova, MD, Prithviraj Bose, MD, Keyur P. Patel, MBBS, PhD, Zeev Estrov, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 4183.

https://doi.org/10.1182/blood.V130.Suppl_1.4183.4183

Published: 2017

Journal Articles

Sustained Long-Lasting Responses after Lenalidomide Discontinuation in Patients with Chronic Lymphocytic Leukemia

Paolo Strati, MD, Alessandra Ferrajoli, MD, William G Wierda, MD PhD, Nitin Jain, MD, Philip A Thompson, MBBS, Susan M. O'Brien, MD, Katy Rezvani, MD PhD, Hagop M. Kantarjian, MD, Jan A. Burger, MD PhD, Christina Hinojosa, Michael J. Keating, MD, Zeev Estrov, MD

Blood (2017) 130 (Supplement 1): 3024.

https://doi.org/10.1182/blood.V130.Suppl_1.3024.3024

Published: 2017

Journal Articles

Efficacy and Safety of Generic Imatinib after Switching from Innovator Imatinib in Patients Treated for Chronic Myeloid Leukemia

Iman Aboudalle, MD, Hagop M. Kantarjian, MD, Jan A. Burger, MD PhD, Zeev Estrov, MD, Maro Ohanian, DO, Elias J. Jabbour, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MBBS, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 2906.

https://doi.org/10.1182/blood.V130.Suppl_1.2906.2906

Published: 2017

Journal Articles

Isolated Extramedullary (EMD) Blastic Transformation of Chronic Myeloid Leukemia (CML-BP) in the TKI Era: Characteristics, Treatments and Outcomes

Ahmad Ghorab, MDMSc, Preetesh Jain, MBBS,MDDM,PhD, Hagop M. Kantarjian, MD, Rashmi Kanagal-Shamanna, MD, Elias J. Jabbour, MD, Koji Sasaki, MD, Tapan Kadia, MD, Guillermo Garcia-Manero, MD, Prithviraj Bose, MD, Musa Yilmaz, MD, Kiran Naqvi, MDMPH, William G Wierda, MD PhD, Srdan Verstovsek, MD PhD, Nitin Jain, MD, Zeev Estrov, MD, Farhad Ravandi, MBBS, Susan M. O'Brien, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 2868.

https://doi.org/10.1182/blood.V130.Suppl_1.2868.2868

Published: 2017

Journal Articles

Correlation of Mutational Profile and Response in Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Pegylated Interferon Alfa 2a As Part of a Prospective Phase II Study

Lucia Masarova, MD, Keyur Patel, MD PhD, Saradhi Mallampathi, PhD, Yawa Dzifa Duose, PhD, Kate J Newberry, PhD, Jorge E. Cortes, MD, Zeev Estrov, MD, Hagop M. Kantarjian, MD, Raja Luthra, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 1640.

https://doi.org/10.1182/blood.V130.Suppl_1.1640.1640

Published: 2017

Journal Articles

CLL Cell-Derived Exosomes Promote Bone Marrow Fibrosis and Inhibit Normal Hematopoietic Colony Proliferation

Uri Rozovski, MD, David M. Harris, Ping Li, PhD, Zhiming Liu, Taghi Manshouri, Ivo Veletic, MD, Carlos Bueso-Ramos, MD PhD, Preetesh Jain, MBBS,MDDM,PhD, Srdan Verstovsek, MD PhD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Prithviraj Bose, MD, Philip A Thompson, MBBS, Nitin Jain, MD, William G Wierda, MD PhD, Michael J. Keating, MD, Zeev Estrov, MD

Blood (2017) 130 (Supplement 1): 1728.

https://doi.org/10.1182/blood.V130.Suppl_1.1728.1728

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Increased Pentraxin-3 Correlates with the Activity of the Neoplastic Clone in Primary Myelofibrosis

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations

Blinatumomab in B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease: Initial Results of a Phase II Trial

Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

Absolute Percent Deviation of IGHV Mutation As a Continuum Is Prognostically Relevant in Patients with CLL

Omacetaxine Mepesuccinate for Patients with Higher-Risk MDS and CMML after Failure of Hypomethylating Agents: A Phase II Trial

Characteristics and Survival of Patients with Chronic Phase Myelofibrosis and Elevated Blasts (5-9%), and the Effect of Therapy with JAK2 Inhibitor Ruxolitinib

Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial

Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center

Overexpression of CD36, Driven By STAT3, Mediates Free Fatty Acid Uptake in CLL Cells

Standardized Targeted Sequencing of 29 Genes with Recurrent Mutations in Chronic Lymphocytic Leukemia (CLL) Helps to Better Define Clinical Correlates and Genomic Hotspots

Pattern of Mutational Changes in Patients with Chronic Phase CML Who Are Treated with Frontline TKI and Transform to Blast Phase CML

The Clinical BET Inhibitor, GS-5829, Is Active Against Chronic Lymphocytic Leukemia As Single Agent and in Combination with B-Cell Receptor Signaling Inhibitors

Non-Driver Mutations and Gene Sequence Variants Identified By Targeted Deep Sequencing in Polycythemia Vera and Essential Thrombocythemia

Sustained Long-Lasting Responses after Lenalidomide Discontinuation in Patients with Chronic Lymphocytic Leukemia

Efficacy and Safety of Generic Imatinib after Switching from Innovator Imatinib in Patients Treated for Chronic Myeloid Leukemia

Isolated Extramedullary (EMD) Blastic Transformation of Chronic Myeloid Leukemia (CML-BP) in the TKI Era: Characteristics, Treatments and Outcomes

Correlation of Mutational Profile and Response in Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Pegylated Interferon Alfa 2a As Part of a Prospective Phase II Study

CLL Cell-Derived Exosomes Promote Bone Marrow Fibrosis and Inhibit Normal Hematopoietic Colony Proliferation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only